Bausch Health Companies Inc.

1 day ago · defenseworld.net

Bausch Health Cos Inc. (NYSE: BHC - Get Free Report) has been given a consensus rating of "Reduce" by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a hold rating on the company. The average 12-month price

4 days ago · defenseworld.net

Engineers Gate Manager LP grew its holdings in Bausch Health Cos Inc. (NYSE: BHC) by 149.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 249,991 shares of the company's stock after purchasing an additional 149,820 shares during the quarter. Engineers

8 days ago · zacks.com

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

14 days ago · prnewswire.com

Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and Kazakhstan. LAVAL, QC, Sept.

29 days ago · businesswire.com

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. “Helping people see better to live better starts with tackling the challenges patients still face every day,” said Bausch + Lomb CEO Brent Saunders. “These results suppor.

1 month ago · zacks.com

Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 month ago · zacks.com

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · seekingalpha.com

Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and enabling margin and EBITDA expansion without unsustainable revenue acceleration.

1 month ago · seekingalpha.com

Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, but balance sheet risks remain paramount. BHC delivered Q2 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and notable margin and cash flow improvements. Despite operational momentum, BHC's $15B long-term debt and $800M H1 interest expense drive speculative credit ratings and analyst skepticism.

1 month ago · zacks.com

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.